Konstantin Kazankov

List of Publications by Year
in descending order

30	1,562	567281 15	477307 29
papers	citations	h-index	g-index

30	30	30	2679
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 145-159.	17.8	571
2	Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology, 2014, 60, 521-530.	7.3	150
3	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 1012-1021.	3.7	128
4	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World Journal of Hepatology, 2019, 11, 138-149.	2.0	122
5	Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver International, 2011, 31, 534-540.	3.9	100
6	The macrophage activation marker <scp>sCD</scp>163 is associated with morphological disease stages in patients with nonâ€alcoholic fatty liver disease. Liver International, 2016, 36, 1549-1557.	3.9	94
7	Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PLoS ONE, 2015, 10, e0137302.	2.5	54
8	Macrophage activation marker soluble <scp>CD</scp>163 and nonâ€alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1293-1300.	2.8	53
9	Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut, 2013, 62, 1231-1232.	12.1	40
10	Timeâ€dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful directâ€acting antiviral therapy of chronic hepatitis C. Journal of Viral Hepatitis, 2020, 27, 28-35.	2.0	36
11	Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 64-73.	1.2	29
12	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 484-491.	2.8	27
13	Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 498-504.	1.2	26
14	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology, 2018, 53, 986-993.	1.5	23
15	Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Frontiers in Medicine, 2020, 7, 615599.	2.6	19
16	Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nationâ€wide Cohort Study. Hepatology, 2021, 74, 2725-2734.	7.3	16
17	High burden of coronary atherosclerosis in patients with cirrhosis. European Journal of Clinical Investigation, 2017, 47, 565-573.	3.4	14
18	Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 2020, 26, 2931-2947.	3.3	11

#	Article	IF	Citations
19	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 635-642.	1.8	10
20	Macrophage markers and innate immunity in cirrhosis. Journal of Hepatology, 2020, 73, 1586-1588.	3.7	8
21	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. Expert Review of Gastroenterology and Hepatology, 2021, 15, 51-64.	3.0	8
22	Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose. Scandinavian Journal of Gastroenterology, 2019, 54, 623-632.	1.5	7
23	Reply. Hepatology, 2015, 61, 735-736.	7.3	4
24	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Rouxâ€enâ€Y gastric bypass. Physiological Reports, 2022, 10, e15157.	1.7	3
25	QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascites. Scandinavian Journal of Gastroenterology, 2019, 54, 1376-1378.	1.5	2
26	Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. American Journal of Physiology - Renal Physiology, 2020, 319, G151-G156.	3.4	2
27	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. Frontiers in Medicine, 2020, 7, 616212.	2.6	2
28	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. Biomarkers in Disease, 2016, , 1-28.	0.1	2
29	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. Biomarkers in Disease, 2017, , 321-348.	0.1	1
30	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. Current Hepatology Reports, 2017, 16, 308-316.	0.9	0